Corona Remedies Limited has officially commenced additional commercial production of tablets and capsules at its Bhayla manufacturing facility on December 22, 2025, at approximately 10:00 a.m., marking a significant milestone in the company's manufacturing expansion strategy.

Capacity Enhancement Details

The pharmaceutical company has successfully increased its production capabilities at the Bhayla facility with substantial capacity additions. The expansion adds 400 million units to the installed capacity and 240 million units to the available capacity.

Production Performance

As of March 31, 2025, the Bhayla facility demonstrated strong operational efficiency with actual production of 561.49 million units against an available capacity of 600 million units, achieving a capacity utilization rate of 93.58%. This high utilization rate reflects the company's effective manufacturing operations and market demand.

Strategic Expansion Impact

The additional commercial production represents a significant milestone in Corona Remedies' strategic expansion plans. The company expects this capacity enhancement to augment upcoming market demands, enhance in-house production capabilities, and improve supply chain agility.

Financial Strategy

The capacity expansion has been entirely funded through internal accruals, highlighting Corona Remedies' strong financial position and self-sustaining growth approach. This internal funding strategy demonstrates the company's ability to finance significant operational expansions without external borrowing or equity dilution.

Corona Remedies, a pharmaceutical company, made a robust debut on the National Stock Exchange (NSE) today, with its shares listing at a significant premium over the initial public offering (IPO) price.

Listing Details

The strong listing reflects positive investor sentiment towards the company and the pharmaceutical sector in general.

Market Impact

The impressive debut of Corona Remedies on the NSE highlights the ongoing interest in the healthcare and pharmaceutical sectors. This successful listing may potentially boost investor confidence in upcoming IPOs, particularly those in the healthcare space.

Company Overview

Detailed financial information is not yet available due to the recent listing. However, Corona Remedies' strong market debut suggests that investors are optimistic about the company's future prospects and growth potential in the pharmaceutical industry.

Investors and market watchers will likely keep a close eye on Corona Remedies' performance in the coming days and weeks as it establishes itself in the public market. As more financial data becomes available, it will provide a clearer picture of the company's operational and financial strengths.

It's important for potential investors to conduct thorough research and consider their risk appetite before making investment decisions based on initial listing performance alone.